$6.36M At-The-Market Offering Launched by Phio Pharmaceuticals, Signaling Significant Dilution
PHIO sits 51% above its 52-week low of $0.813.
Summary
Phio Pharmaceuticals has launched an At-The-Market (ATM) offering to sell up to $6.36 million of common stock through H.C. Wainwright. This offering represents a substantial portion of the company's current market capitalization, indicating significant potential dilution for existing shareholders. While it provides flexible access to capital, which is crucial for a development-stage biotech, the dilutive effect is likely to exert downward pressure on the stock. This follows the company's recent 10-K filing which noted successful capital raises totaling $20.6 million that resolved going concern doubts, suggesting a continued need for funding to advance its pipeline, including the lead drug candidate PH-762 for which a cGMP manufacturing agreement was recently announced. Traders should monitor the pace and pricing of the ATM sales and any updates on the use of proceeds.
At the time of this announcement, PHIO was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1M. The 52-week trading range was $0.81 to $4.19. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.